<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00658164</url>
  </required_header>
  <id_info>
    <org_study_id>111.2007</org_study_id>
    <nct_id>NCT00658164</nct_id>
  </id_info>
  <brief_title>Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <brief_summary>
    <textblock>
      Patients will be randomized to lifestyle changes alone or lifestyle changes associated with&#xD;
      iron depletion.&#xD;
&#xD;
      Iron depletion will be achieved by removing 350 cc of blood every 10-15 days according to&#xD;
      baseline hemoglobin values and venesection tolerance, until ferritin &lt; 30 ng/ml and&#xD;
      transferrin saturation &lt; 25%. Weekly phlebotomies will be allowed for carriers of the C282Y&#xD;
      HFE mutation. Smaller phlebotomies (250 cc) will be allowed for carriers of beta-thalassaemia&#xD;
      trait. Maintenance phlebotomies (as much as required) will then be instituted to keep iron&#xD;
      stores depleted (ferritin &lt; 50 ng/ml and transferrin saturation &lt; 25%, MCV &lt;85 fl). Before&#xD;
      starting treatment, patients will undergo ECG, and in the presence of hyperglycemia or&#xD;
      hypertension also echocardiography (see exclusion criteria).&#xD;
&#xD;
      Change in diabetes medication dosage or start of new therapy will be allowed for HbA1C values&#xD;
      &lt;6% or ≥ 7%. According to accepted criteria, previously untreated patients should be treated&#xD;
      with metformin. If possible, newly diagnosed hypertension should be treated with&#xD;
      Ace-inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine in a 24 month controlled study whether iron depletion by phlebotomy improves insulin sensitivity, and thereby reduces hepatic steatosis and inflammation in subjects with nonalcoholic steatohepatitis</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of iron depletion on glucose tolerance status. Glucose tolerance will be determined by OGTT in subjects without type 2 diabetes (T2D), and by HbA1c levels and the change in dosage of pharmacological therapy in those with T2D.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Iron depletion treatment</intervention_name>
    <description>Effect of iron depletion by phlebotomy plus lifestyle changes vs. lifestyle changes alone on liver damage in patients with nonalcoholic fatty liver disease with increased iron stores</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 &lt; 75 years&#xD;
&#xD;
          -  Ferritin &gt; 250 ng/ml and/or stainable iron at biopsy&#xD;
&#xD;
          -  NAS ≥ 2 and/or NAS 1 and stage≥1 at liver histology&#xD;
&#xD;
          -  Willingness to maintain diet and exercise during the full course of the study&#xD;
&#xD;
          -  Written informed consent to participate to the study and to have the specific genetic&#xD;
             tests performed&#xD;
&#xD;
          -  Ability to comply with all study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  Diagnosis of or a history of:&#xD;
&#xD;
          -  Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of&#xD;
             diabetes, e.g. Cushing's syndrome or acromegaly&#xD;
&#xD;
          -  Acute metabolic complication such as ketoacidosis or hyperosmolar state within the&#xD;
             past 6 months&#xD;
&#xD;
          -  Alcohol consumption &gt; 20 g/day for females and &gt; 30 g/day for males&#xD;
&#xD;
          -  BMI ≥ 35 Kg/ m2&#xD;
&#xD;
          -  Other liver disease such as viral hepatitis, autoimmune hepatitis, Wilson disease, as&#xD;
             defined by ceruloplasmin below normal limits and liver histology consistent with&#xD;
             Wilson disease. Alpha-1-antitrypsin deficiency as defined by alpha-1-antitrypsin level&#xD;
             less than 80 mg/dl or PiZ/PiZ or PiZ/PiS genotype. *Hemochromatosis, as defined by&#xD;
             homozygosity for the C282Y HFE mutation or compound heterozygosity for C282Y/H63D&#xD;
             mutations or Hepatic Iron Index ≥ 1.9.&#xD;
&#xD;
          -  Advanced liver disease (Child B/C cirrhosis), portal hypertension, hepatocellular&#xD;
             carcinoma.&#xD;
&#xD;
          -  Congestive heart failure (NYHA I-IV) and unstable ischemic heart disease, systolic&#xD;
             dysfunction (ejection fraction &lt; 45%)&#xD;
&#xD;
          -  Any of the following ECG abnormalities: II or III degree Atrial Ventricular *Block,&#xD;
             QT&gt;500msec, repolarization defect suggestive of ischemia&#xD;
&#xD;
          -  Malignancy within the last 5 years&#xD;
&#xD;
          -  Serum creatinine levels &gt; 1.5 mg/dl males, &gt; 1.4 mg/dl females&#xD;
&#xD;
          -  TSH outside of normal range&#xD;
&#xD;
          -  Use of drugs known to induce NAFLD: corticosteroids, methotrexate, zidovudine,&#xD;
             amiodarone, GH, estrogens, tamoxifene, tetracycline&#xD;
&#xD;
          -  Lipodystrophy, dysbetalipoproteinemia, inflammatory bowel disease, HIV infection&#xD;
&#xD;
          -  Basal hemoglobin levels &lt; 11 g/dl&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Silvia Fargion, prof</last_name>
    <phone>39-02-5503-3301</phone>
    <email>silvia.fargion@unimi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>U.O. Medicina Interna 1/B</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Fargion, Prof.</last_name>
      <phone>39-02-5503-3301</phone>
      <email>silvia.fargion@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Fargion, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Valenti, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>April 9, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>April 11, 2008</last_update_submitted>
  <last_update_submitted_qc>April 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Fondazione Ospedale Maggiore Policlinico Mangiagalli e Regina Elena</name_title>
    <organization>Prof. Silvia Fargion</organization>
  </responsible_party>
  <keyword>Nonalcoholic fatty liver disease associated with increased iron stores</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

